Therapeutic antibodies and related products: choosing the right structure for success

被引：9

作者：

Beck, Alain ^{[1
]}

Wagner-Rousset, Elsa ^{[1
]}

Wurch, Thierry ^{[1
]}

Corvaia, Nathalie ^{[1
]}

机构：

[1] Ctr Immunol Pierre Fabre, F-74160 St Julien En Genevois, France

来源：

M S-MEDECINE SCIENCES | 2009年 / 25卷 / 12期

关键词：

MONOCLONAL-ANTIBODIES; HUMAN IGG2; ANTIINFLAMMATORY ACTIVITY; MASS-SPECTROMETRY; GLYCOSYLATION; ISOTYPE; BINDING; HETEROGENEITY; DISCOVERY; DOMAINS;

D O I：

10.1051/medsci/200925121024

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Therapeutic antibodies and related products: choosing the right structure for success Monoclonal antibodies (mAb) and related-products represent the fastest growing class of therapeutics in the biotechnological and pharmaceutical industry. In just as short as 20 years, more than 30 immunoglobulins (IgG) and derivatives have been approved in a wide range of indications (oncology, inflammation and auto-immunity, transplantation, angioplasty, hematology, ophthalmology, viral infections, allergy). The mAb structure toolbox contains mouse, chimeric, humanized and human antibodies from different isotypes (IgG1, 2 and 4), as well as IgG-related products (immunoconjugates, radio-immunoconjugates, Fab fragments, Fc-fusion proteins and peptides, bispecifics). Furthermore from a structural point of view, mAb glycosylation is linked to their production systems and may impact on their effector functions and immunogenicity. Based on the current knowledge, choosing the right antibody format, isotype and glycosylation profile are some of the key issues to address early during the lead selection.

引用

页码：1024 / 1032

页数：9

共 48 条

[1] What's fueling the biotech engine-2007 [J].

Aggarwal, Saurabh .

NATURE BIOTECHNOLOGY, 2008, 26 (11) :1227-1233

[2] A SINGLE AMINO-ACID SUBSTITUTION ABOLISHES THE HETEROGENEITY OF CHIMERIC MOUSE/HUMAN (IGG4) ANTIBODY [J].

ANGAL, S ;

KING, DJ ;

BODMER, MW ;

TURNER, A ;

LAWSON, ADG ;

ROBERTS, G ;

PEDLEY, B ;

ADAIR, JR .

MOLECULAR IMMUNOLOGY, 1993, 30 (01) :105-108

[3] Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc [J].

Anthony, Robert M. ;

Nimmerjahn, Falk ;

Ashline, David J. ;

Reinhold, Vernon N. ;

Paulson, James C. ;

Ravetch, Jeffrey V. .

SCIENCE, 2008, 320 (5874) :373-376

[4] Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NSO cells [J].

Beck, A ;

Bussat, MC ;

Zorn, N ;

Robillard, V ;

Klinguer-Hamour, C ;

Chenu, S ;

Goetsch, L ;

Corvaïa, N ;

Van Dorsselaer, A ;

Haeuw, JF .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 819 (02) :203-218

[5] Editorial: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic [J].

Beck, A. ;

Wurch, T. ;

Corvaia, N. .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2008, 9 (06) :421-422

[6]

BECK A, 2008, SCREENING TRENDS DRU, V9, P18

[7]

BECK A, 2009, MABS LANDES BIOSCIEN, V5, P394

[8]

BECK A, 2010, EXPERT OP D IN PRESS

[9] Peptides as tools and drugs for immunotherapies [J].

Beck, Alain ;

Klinguer-Hamour, Christine ;

Bussat, Marie-Claire ;

Champion, Thierry ;

Haeuw, Jean-Francois ;

Goetsch, Liliane ;

Wurch, Thierry ;

Sugawara, Masae ;

Milon, Alain ;

Van Dorsselaer, Alain ;

Nguyen, Thien ;

Corvaiea, Nathalie .

JOURNAL OF PEPTIDE SCIENCE, 2007, 13 (09) :588-602

[10] Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins [J].

Beck, Alain ;

Wagner-Rousset, Elsa ;

Bussat, Marie-Claire ;

Lokteff, Maryline ;

Klinguer-Hamour, Christine ;

Haeuw, Jean-Francois ;

Goetsch, Liliane ;

Wurch, Thierry ;

Van Dorsselaer, Alain ;

Corvaia, Nathalie .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2008, 9 (06) :482-501

← 1 2 3 4 5 →